Identification of Tengfu Jiangya Tablet Target Biomarkers with Quantitative Proteomic Technique

Abstract EN

Tengfu Jiangya Tablet (TJT) is a well accepted antihypertension drug in China and its major active components were Uncaria total alkaloids and Semen Raphani soluble alkaloid.

To further explore treatment effects mechanism of TJT on essential hypertension, a serum proteomic study was performed.

Potential biomarkers were quantified in serum of hypertension individuals before and after taking TJT with isobaric tags for relative and absolute quantitation (iTRAQ) coupled two-dimensional liquid chromatography followed electrospray ionization-tandem mass spectrometry (2D LC-MS/MS) proteomics technique.

Among 391 identified proteins with high confidence, 70 proteins were differentially expressed (fold variation criteria, >1.2 or <0.83) between two groups (39 upregulated and 31 downregulated).

Combining with Gene Ontology annotation, KEGG pathway analysis, and literature retrieval, 5 proteins were chosen as key target biomarkers during TJT therapeutic process.

And the alteration profiles of these 5 proteins were verified by ELISA and Western Blot.

Proteins Kininogen 1 and Keratin 1 are members of Kallikrein system, while Myeloperoxidase, Serum Amyloid protein A, and Retinol binding protein 4 had been reported closely related to vascular endothelial injury.

Our study discovered 5 target biomarkers of the compound Chinese medicine TJT.

Secondly, this research initially revealed the antihypertension therapeutic mechanism of this drug from a brand-new aspect.